Oxaliplatin effects on the DNA molecule studied by force spectroscopy

In the present study we investigated the binding of the anticancer compound Oxaliplatin to DNA. Using optical tweezers to perform single molecule force spectroscopy, we determined the changes of the mechanical parameters of DNA complexes formed with Oxaliplatin, at high and low ionic strengths. The interaction mechanism and the physical chemistry of the binding were determined from these measurements. In addition, kinetic information on covalent diadduct formation and on DNA compaction by Oxaliplatin were also obtained. All these results were critically compared to those obtained for the related anti-neoplastic compounds Cisplatin and Carboplatin, previously determined under similar experimental conditions. These results provide new information about the action of platinum-based compounds on DNA, being useful to the improvement of current chemotherapies and to the design of novel correlated drugs.

• Publication year

  2019

• Venue

  Biomedical engineering and physics express

• Publication date

  2019-08-09

• Fields of study

  Medicine, Physics, Chemistry

• Identifiers
  DOI 10.1088/2057-1976/ab37ce
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

  2023cited by this paper
• Carboplatin as an alternative to Cisplatin in chemotherapies: New insights at single molecule level.

  2018cited by this paper
• DNA‐doxorubicin interaction: New insights and peculiarities

  2017cited by this paper
• Force spectroscopy unravels the role of ionic strength on DNA-cisplatin interaction: Modulating the binding parameters.

  2017cited by this paper
• Extracting physical chemistry from mechanics: a new approach to investigate DNA interactions with drugs and proteins in single molecule experiments.

  2015cited by this paper
• Raman spectroscopic evaluation of DNA adducts of a platinum containing anticancer drug.

  2014cited by this paper
• Oxaliplatin and Its Enantiomer Induce Different Condensation Dynamics of Single DNA Molecules

  2013cited by this paper
• Quantitative assessment of the interplay between DNA elasticity and cooperative binding of ligands.

  2012cited by this paper
• DNA-cisplatin interaction studied with single molecule stretching experiments.

  2012cited by this paper
• Speciation of oxaliplatin adducts with DNA nucleotides.

  2011cited by this paper
• In Vitro Cytotoxic-Active Platinum(II) Complexes Derived from Carboplatin and Involving Purine Derivatives

  2010cited by this paper
• Cisplatin induces loop structures and condensation of single DNA molecules

  2009cited by this paper
• Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

  2008cited by this paper
• Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations.

  2007cited by this paper
• On the hydrolysis mechanism of the second-generation anticancer drug carboplatin.

  2007cited by this paper
• Development of a liquid chromatography-electrospray ionization tandem mass spectrometry method for detecting oxaliplatin-DNA intrastrand cross-links in biological samples.

  2007cited by this paper
• Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.

  2006cited by this paper
• Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma.

  2006cited by this paper
• Cisplatin : chemistry and biochemistry of a leading anticancer drug

  2006cited by this paper
• Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.

  2005cited by this paper
• Cisplatin induces DNA double-strand break formation in Escherichia coli dam mutants.

  2005cited by this paper
• Cancer Statistics, 2004

  2004cited by this paper
• A review of oxaliplatin and its clinical use in colorectal cancer

  2004cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer.

  2002cited by this paper
• DNA bending and unwinding due to the major 1, 2-GG intrastrand cross-link formed by antitumor cis-diamminedichloroplatinum(II) are flanking-base independent

  2002cited by this paper
• Alkaline hydrolysis of oxaliplatin--isolation and identification of the oxalato monodentate intermediate.

  2002cited by this paper
• 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex.

  2001cited by this paper
• Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5'-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry.

  2001cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

  1999cited by this paper
• Antitumour activity of oxaliplatin in neuroblastoma cell lines.

  1999cited by this paper
• Oxaliplatin: mechanism of action and antineoplastic activity.

  1998cited by this paper
• Activity of oxaliplatin against human tumor colony-forming units.

  1998cited by this paper
• Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

  1995cited by this paper
• In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.

  1993cited by this paper
• New Cisplatin Analogues in Development

  1993cited by this paper
• Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

  1992cited by this paper
• Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

  1992cited by this paper
• Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

  1990cited by this paper
• Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data.

  1989cited by this paper
• Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks.

  1988cited by this paper
• Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study.

  1987cited by this paper
• Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

  1986cited by this paper
• Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.

  1985cited by this paper
• Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum (II) with DNA, by anion-exchange chromatography after enzymatic degradation.

  1982cited by this paper
• Separation and characterization of products resulting from the reaction of cis-diamminedichloroplatinum (II) with deoxyribonucleosides.

  1982cited by this paper
• Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives

  1978cited by this paper
• New platinum complexes with anti-tumour activity.

  1972cited by this paper
• Platinum Compounds: a New Class of Potent Antitumour Agents

  1969cited by this paper
• Ueber die Einwirkung des Ammoniaks auf Platinchlorür

  year unknowncited by this paper
• Stretching DNA

  year unknowncited by this paper

• Caffeine Enhances the Toxicity of Platinum-Based Drugs at the Molecular Level Even Outside of the Intracellular Environment: A Single-Molecule Force Spectroscopy Study.

  2022cites this paper
• Transplatin ineffectiveness against cancer from a molecular perspective: A single-molecule force-spectroscopy study.

  2020cites this paper
• On the use of Europium (Eu) for designing new metal-based anticancer drugs.

  2020cites this paper